Results
Trial
Research Area
Duration
Locations
A5404: SARS-CoV-2 Immune Responses after COVID-19 Therapy and Subsequent Vaccine
Right now there is no medicine proven to treat COVID-19 in people who are not sick enough to be hospitalized.…
Closed to accrual
COVID-19 and Mpox
A5406 is a study for people with pulmonary drug-sensitive (DS) tuberculosis (TB) without evidence of resistance to the TB drugs…
Closed to accrual
Tuberculosis
Participants will be in this study for about 48 weeks. This includes 17 weeks of anti-TB study treatment, and ART from week 6 to week 48.
A5409: Novel Regimens for Pulmonary TB
The standard of care (SOC) treatment of tuberculosis (TB) was developed over 40 years ago, and the treatment is long…
Open and enrolling
Tuberculosis
Participants will be in this study for about 52 weeks. This includes a total of 26 weeks of TB treatment. If assigned to the experimental arm, participants will have 8 weeks of experimental treatment, followed by 18 weeks of SOC treatment. If assigned to the SOC arm, participants will have 26 weeks of SOC treatment.
A5413: Dasatinib for HIV-1 Reservoir Reduction
To determine if dasatinib is safe and well tolerated in people with HIV, and to see if dasatinib can reduce…
Open and enrolling
HIV Cure, Treatment Experienced
36 weeks
To find out whether tuberculosis (TB) can be treated safely within a shorter time using newer medicines and whether the…
Active, Not Recruiting
Tuberculosis
About 72 weeks (about 1 year and 4 months)
People with HIV can have an increase in inflammation in their body organs even after taking anti-HIV medicines (ART, or…
Closed to accrual
Treatment Experienced
24 weeks
A5417: Antiretrovirals Combined with Antibodies for HIV-1 Cure In Africa
This study enrolls people living with HIV in sub-Saharan Africa at the time that they are about to start antiretroviral…
Closed to accrual
Treatment Naïve
Up to 180 weeks.
A5418: Study of Tecovirimat for Human Mpox Virus
A5418 (STOMP) is a study of tecovirimat (also known as TPOXX) for the treatment of human monkeypox virus (HMPXV) disease.
Closed to accrual
COVID-19 and Mpox
A5422: CH505 TF chTrimer Vaccination in Adults Living with HIV-1 on Suppressive ART
This study is looking to see if an investigational anti-HIV vaccine (stabilized CH505 TF chTrimer) is safe and well-tolerated in…
temporary-closed
Treatment Experienced
Participants will be on study for about 2 years (100 weeks).
Menopausal hormone therapy (MHT) is considered the most effective therapy for vasomotor symptoms (VMS; also known as hot flashes and…
Open and enrolling
Treatment Experienced
Participants will be in this study for approximately 5 months.
A5426: Improving Physical Ability and Cellular Senescence Elimination in HIV
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib…
Closed to accrual
HIV comorbidities and complications
The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects.